Nibash Budhathoki 5913663 photo

Nibash Budhathoki, M.D., MBBS

  • Hematology Oncology
  • Medical Oncology

Accepting New Patients

UnityPoint Provider


  • Hospital Affiliations:
    • St. Luke's-Sioux City
  • Gender: Male

About Nibash Budhathoki, M.D., MBBS

Biography

“I became an oncologist because I have experienced personal tragedy due to cancer. Having seen what patients and their family members go through during the most challenging times of their lives, I wanted to help people in their journey.”

Nibash Budhathoki, MD, MBBS joined the June E. Nylen Cancer Center in 2021 from NYU Langone Hospital in Long Island, New York. Dr. Budhathoki had previously worked for two years as a physician in a rural setting in Nepal and found that experience very gratifying and fulfilling. It was important to him to provide cancer care services in underserved areas hence, choosing JENCC as it is the only cancer center in the Siouxland region that provides comprehensive cancer care to patients.

Dr. Budhathoki considers himself hard working, compassionate, empathetic, and always puts his patients first. His parents were farmers who traveled into the city for better educational opportunities for him and his siblings and invested heavily in their education. Dr. Budhathoki and his siblings are the first-generation high school graduates in their family.

Dr. Budhathoki is married and he enjoys being outdoors and playing sports, especially tennis and soccer.

Qualifications

Education

Medical School

Kathmandu Medical College, Kathmandu, Nepal

Residency

Interfaith Medical Center, New York, NY

Fellowship

NYU Langone Hospital, Long Island, NY

Board Certifications

Medical Oncology

American Board of Internal Medicine

Publications

Dr. Budhathoki has received several honors for his integral efforts in research publications:

  • Impact of immune checkpoint and BRAF inhibitors on the incidence of second primary malignancies (SPM) in melanoma. (received the 2020 Conquer Cancer Merit Award from Conquer Cancer®, the ASCO Foundation and the 2020 ASCO Scientific Program Committee)
  • Risk for SARS-CoV-2 infection in patients with breast cancer treated with chemotherapy, biologic therapy or active surveillance: Patient outcomes from multicenter institution in New York. (received the 2021 Conquer Cancer Merit Award from Conquer Cancer®, the ASCO Foundation, and the 2021 ASCO Scientific Program Committee)

Patient Ratings and Comments

Ratings and comments come from real patient experience surveys. Learn more about our provider ratings and reviews program.